Lexicon Pharmaceuticals Inc
LXRXHealthcare|Biotechnology|USA
$2.23
-0.03 (-1.33%)
Tangible Book
$0.37
Upcoming Data Readouts (4)
Sep 2026
Est. completion
Early P1Platelet Function and Reactivity Tests
Comparison of Antiplatelet Effects of Sotagliflozin to FDA-approved Antiplatelet Drugs
NCT06933056n=20
Oct 2027
Est. completion
P2Type 1 Diabetes
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156n=320
Jan 2028
Est. completion
P1P2Type 1 Diabetes
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
NCT05696366n=24
Dec 2028
Est. completion
P3Diabetic Nephropathies
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
NCT06217302n=150